Evidence Level
Moderate
Ginkgo biloba is among the most extensively studied herbal medicines, with hundreds of clinical trials. The large GuidAge trial (n=2,854) found that while ginkgo did not prevent dementia onset in healthy elderly, it reduced risk in a compliant subgroup. A 2014 Cochrane-quality meta-analysis of EGb 761 confirmed modest but statistically significant cognitive benefits in patients with existing cognitive impairment. The GEM trial (n=3,069) in the US found no prevention benefit in healthy elderly. The European medical consensus favors ginkgo as an evidence-based treatment for mild-to-moderate dementia and cognitive decline.